In parallel, liquid biopsy analysis has a significant contribution to the management of lung cancer patients [57] and the detection of EGFR mutations in plasma cfDNA is now used on a routine basis for the stratification of NSCLC patients [58, 59]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.